TSAO derivatives, inhibitors of HIV-1 reverse transcriptase dimerization: recent progress

Area of Science:

• Virology
• Medicinal Chemistry
• Drug Discovery

Background:

• Human immunodeficiency virus (HIV) infection requires new treatments effective against resistant strains and novel targets.
• HIV-1 reverse transcriptase (RT) is crucial for viral replication and a key target for antiviral drugs.
• The dimeric form of HIV-1 RT is essential for its activity, making dimerization a potential therapeutic target.

Purpose of the Study:

• To review recent advancements in TSAO derivatives as non-nucleoside RT inhibitors (NNRTIs).
• To explore TSAO derivatives that target the p66/p51 heterodimer interface of HIV-1 RT.
• To enhance the interaction of TSAO molecules with the RT dimer interface for improved antiviral activity.

Main Methods:

• Focus on TSAO derivatives, a class of highly functionalized nucleosides.
• Investigate TSAO molecules' selective interaction with the p51 subunit of HIV-1 RT.
• Analyze TSAO's interference with the essential dimerization process of HIV-1 RT.

Main Results:

• TSAO derivatives are non-nucleoside RT inhibitors (NNRTIs) with unique selectivity for HIV-1.
• These compounds interact specifically at the p66/p51 heterodimer interface.
• TSAO molecules were the first small, non-peptidic agents shown to inhibit RT dimerization.

Conclusions:

• TSAO derivatives represent a promising class of antiviral agents targeting HIV-1 RT dimerization.
• Further development of TSAO derivatives could lead to new combination therapies for HIV.
• Enhancing TSAO interaction with the RT dimer interface is key for developing next-generation HIV drugs.